Preview Mode Links will not work in preview mode

Mar 31, 2020

Prostate Cancer Update, Issue 1, 2020 — Part 2: Our interview with Dr Fizazi highlights the following topics as well as cases from his practice:

  • Case: A man in his early 70s with nonmetastatic CRPC receives darolutamide in combination with ADT on the ARAMIS trial (00:00)
  • Effect of PSA doubling time on prognosis of patients with nonmetastatic CRPC (02:40)
  • Results of the Phase III PROSPER, SPARTAN and ARAMIS trials evaluating enzalutamide, apalutamide and darolutamide, respectively, for patients with nonmetastatic CRPC (04:50)
  • Tolerability of enzalutamide, apalutamide and darolutamide (08:49)
  • Activity and side-effect profile of darolutamide for nonmetastatic CRPC (15:47)
  • Approaches to preventing bone loss in men receiving ADT (19:03)
  • Optimal integration of radium-223 into current mCRPC treatment algorithms (20:55)
  • Efficacy and safety with the combination of radium-223 and abiraterone or enzalutamide for mCRPC (23:20)
  • Selection and sequencing of therapy for patients with mCRPC; role of enzalutamide for patients who experience disease relapse on abiraterone and vice versa (26:12)
  • Results of the CARD study: Cabazitaxel versus enzalutamide or abiraterone for patients with mCRPC previously treated with docetaxel who experienced rapid disease progression on a prior androgen receptor-targeted agent (28:47)
  • Role of AR-V7 in clinical decision-making for patients with disease progression on secondary hormonal therapy (30:39)
  • Diagnosis and incidence of metastasis in men presenting with HSPC (33:18)
  • STAMPEDE: Radiation therapy to the primary tumor improves survival for the subgroup of patients with newly diagnosed mPC and low metastatic burden (37:18)
  • Efficacy of chemotherapy or secondary hormonal therapy in combination with ADT for patients with mHSPC (40:25)
  • Activity of antiandrogens for patients with PC (43:55)
  • Role of taxanes in the management of PC; comparison of the efficacy and tolerability of cabazitaxel versus docetaxel (46:50)
  • Germline and somatic testing for patients with mPC (51:44)
  • Case: A man in his late 70s with mCRPC and a germline BRCA2 mutation achieves a good response to a PARP inhibitor on a clinical trial (53:45)
  • Efficacy and tolerability of olaparib, rucaparib and niraparib in patients with mPC (59:16)
  • Activity of platinum-based chemotherapy for patients with mPC and BRCA mutations (1:03:44)
  • Potential benefit of PARP inhibitors in patients with PC and alternative DNA damage repair alterations (eg, ATM, CDK12); results from the PROfound trial (1:06:32)

CME information and select publications